Somatostatin receptor subtypes 2 and 5 differentially suppressed GHRH-stimulated versus GHRP-stimulated GH secretion in a clinical study, revealing pathway-specific somatostatin inhibition that explains GH pulse regulation.
Key findingSST2/SST5 receptor activation differentially suppressed GHRH-stimulated and GHRP-2-stimulated GH secretion patterns in healthy men, with different eff
What the researchers found
SST2/SST5 receptor activation differentially suppressed GHRH-stimulated and GHRP-2-stimulated GH secretion patterns in healthy men, with different effects on GH mass, frequency, and regularity — revealing receptor-specific modulation of the two GH-releasing pathways.
Why it matters
Advances understanding of ghrp, hormone-optimization, receptor-signaling, clinical-trials with translational implications.
How the study worked
clinical-trial study examining ghrp and hormone-optimization.
What this study cannot tell us
Study-specific limitations apply; see abstract for details.
How to read the evidence
moderate evidence from clinical-trial study design.
When this study was published
Published in 2004.
The bigger picture
Contributes to the growing body of peptide research with implications for clinical development and therapeutic applications.
Questions still open
- Further research needed to confirm and extend these findings.
- Clinical translation and safety need evaluation.
- Optimal dosing and delivery require characterization.
Common questions
What was the main focus of this study?
What was discovered?
Read the original research
Activation of somatostatin-receptor subtype-2/-5 suppresses the mass, frequency, and irregularity of growth hormone (GH)-releasing peptide-2-stimulated GH secretion in men.
The Journal of clinical endocrinology and metabolism, 89(9), 4581-7
Citation
Iranmanesh, Ali; Bowers, Cyril Y; Veldhuis, Johannes D. (2004). Activation of somatostatin-receptor subtype-2/-5 suppresses the mass, frequency, and irregularity of growth hormone (GH)-releasing peptide-2-stimulated GH secretion in men.. The Journal of clinical endocrinology and metabolism, 89(9), 4581-7.